315 related articles for article (PubMed ID: 29353455)
21. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
Huang Y
Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.
Theendakara V; Peters-Libeu CA; Bredesen DE; Rao RV
Mol Neurobiol; 2018 Jun; 55(6):5243-5254. PubMed ID: 28879423
[TBL] [Abstract][Full Text] [Related]
23. ApoE4: an emerging therapeutic target for Alzheimer's disease.
Safieh M; Korczyn AD; Michaelson DM
BMC Med; 2019 Mar; 17(1):64. PubMed ID: 30890171
[TBL] [Abstract][Full Text] [Related]
24. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
25. Exploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimer's disease.
Behl T; Kaur D; Sehgal A; Singh S; Makeen HA; Albratty M; Abdellatif AAH; Dachani SR; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112773. PubMed ID: 35245734
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology.
Mahley RW; Huang Y
Acta Neurol Scand Suppl; 2006; 185():8-14. PubMed ID: 16866905
[TBL] [Abstract][Full Text] [Related]
27. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease.
Mahley RW; Huang Y; Weisgraber KH
Curr Alzheimer Res; 2007 Dec; 4(5):537-40. PubMed ID: 18220516
[TBL] [Abstract][Full Text] [Related]
28. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
[TBL] [Abstract][Full Text] [Related]
29. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.
Salomon-Zimri S; Glat MJ; Barhum Y; Luz I; Boehm-Cagan A; Liraz O; Ben-Zur T; Offen D; Michaelson DM
J Alzheimers Dis; 2016 Jun; 53(4):1443-58. PubMed ID: 27372644
[TBL] [Abstract][Full Text] [Related]
30. Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: Relevance to accumulation of Aβ in Alzheimer's disease.
Zekonyte J; Sakai K; Nicoll JA; Weller RO; Carare RO
Biochim Biophys Acta; 2016 May; 1862(5):1047-53. PubMed ID: 26327683
[TBL] [Abstract][Full Text] [Related]
31. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
[TBL] [Abstract][Full Text] [Related]
32. Endo-lysosomal dysregulations and late-onset Alzheimer's disease: impact of genetic risk factors.
Van Acker ZP; Bretou M; Annaert W
Mol Neurodegener; 2019 Jun; 14(1):20. PubMed ID: 31159836
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E4 causes early olfactory network abnormalities and short-term olfactory memory impairments.
Peng KY; Mathews PM; Levy E; Wilson DA
Neuroscience; 2017 Feb; 343():364-371. PubMed ID: 28003161
[TBL] [Abstract][Full Text] [Related]
34. Label-free detection of ApoE4-mediated β-amyloid aggregation on single nanoparticle uncovering Alzheimer's disease.
Kang MK; Lee J; Nguyen AH; Sim SJ
Biosens Bioelectron; 2015 Oct; 72():197-204. PubMed ID: 25982728
[TBL] [Abstract][Full Text] [Related]
35. Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease.
Rohn TT
Int J Mol Sci; 2013 Jul; 14(7):14908-22. PubMed ID: 23867607
[TBL] [Abstract][Full Text] [Related]
36. Brain aging and Aβ₁₋₄₂ neurotoxicity converge via deterioration in autophagy-lysosomal system: a conditional Drosophila model linking Alzheimer's neurodegeneration with aging.
Ling D; Salvaterra PM
Acta Neuropathol; 2011 Feb; 121(2):183-91. PubMed ID: 21076961
[TBL] [Abstract][Full Text] [Related]
37. Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction?
Peric A; Annaert W
Acta Neuropathol; 2015 Mar; 129(3):363-81. PubMed ID: 25556159
[TBL] [Abstract][Full Text] [Related]
38. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits.
Yang DS; Stavrides P; Saito M; Kumar A; Rodriguez-Navarro JA; Pawlik M; Huo C; Walkley SU; Saito M; Cuervo AM; Nixon RA
Brain; 2014 Dec; 137(Pt 12):3300-18. PubMed ID: 25270989
[TBL] [Abstract][Full Text] [Related]
39. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease.
Nixon RA
FASEB J; 2017 Jul; 31(7):2729-2743. PubMed ID: 28663518
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis.
Yang DS; Stavrides P; Mohan PS; Kaushik S; Kumar A; Ohno M; Schmidt SD; Wesson DW; Bandyopadhyay U; Jiang Y; Pawlik M; Peterhoff CM; Yang AJ; Wilson DA; St George-Hyslop P; Westaway D; Mathews PM; Levy E; Cuervo AM; Nixon RA
Autophagy; 2011 Jul; 7(7):788-9. PubMed ID: 21464620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
